 OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2021 GLOBE NEWSWIRE -- Oxford Immunotec Global PLC Nasdaq: OXFD the Company, a global, high-growth diagnostics company, announce the start of a collaboration with Valneva. The Company will perform T cell testing on participants receiving Valnevas inactivated whole-virus COVID-19 vaccine candidate VLA2001 with the research use only T-SPOT Discovery SARS-CoV-2 test. The VLA2001-201 study is a randomized Phase III clinical study designed to evaluate the safety, tolerability and immunogenicity of an inactivated SARS-CoV-2 virus vaccine candidate in healthy subjects, the first study of its kind performed in Europe. 